The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
Provided herein are method of treating, ameliorating, or delaying at least one symptom of a genetic blood disorder, e.g. sickle cell disorder or thalassemia, in a patient in need thereof, comprising administering a therapeutically effective amount of a Jak2 inhibitor. Also provided in part is a method of reducing an enlarged spleen in a patient suffering from thalassemia, comprising administering a therapeutically effective amount of a Jak2 inhibitor.
US8133900B2
申请人:——
公开号:US8133900B2
公开(公告)日:2012-03-13
Iron-Catalyzed Intermolecular Hydroamination of Styrenes
作者:C. Bryan Huehls、Aijun Lin、Jiong Yang
DOI:10.1021/ol5013907
日期:2014.7.18
formal hydroamination of alkenes has been developed. It features O-benzoyl-N,N-dialkylhydroxylamines as the electrophilic nitrogen source and cyclopentylmagnesium bromide as the reducing agent for intermolecularhydroamination of styrene and derivatives with good yield and excellent Markovnikov regioselectivity. The reaction presumably proceeds through the iron-catalyzed hydrometalation of styrene followed